– Study Results Validate the Hypothesis That TTR Silencing by an RNAi Therapeutic has the Potential to be an Effective Approach for Treating Cardiomyopathy of ATTR Amyloidosis – – Patisiran met ...
San José Democrat Zoe Lofgren joined a chorus of experts decrying the controversial vaccine trial after the administration ...
− Echocardiographic and Cardiac Biomarker Data From the HELIOS-B Study Presented Today Support the Potential of Vutrisiran in ATTR-CM – − Vutrisiran Significantly Improved Echocardiographic ...
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that results from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) ...
MedPage Today on MSN
CDC Gives Danish Researchers $1.6M to Study Hep B Vaccine Birth Dose in Africa
Researchers have raised concerns about an unusual federal grant made to Danish researchers to study the hepatitis B vaccine birth dose in Africa. The CDC awarded $1.6 million over 5 years to an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback